Skip to content Skip to sidebar Skip to footer

Newsletter

Life Sciences

Dimerix And Its DMX-200 (Qytovra) Therapy Approach Their Most Important Catalyst

After several years of advancing DMX-200/Qytovra, Dimerix is entering the most consequential chapter of its life. The upcoming blinded statistical powering analysis for ACTION3 is the moment where all of that groundwork will likely pay off. Dimerix has been advancing DMX-200/Qytovra for several years DMX-200 is a targeted anti‑inflammatory therapy designed to block the CCR2 pathway…

ByNick SundichApril 21, 2026

How To Read a Balance Sheet As An Investor: The 7 Questions Prudent Investors Need to Ask!

Knowing how to read a balance sheet is a key skill investors need to know, because the balance sheet is the most underrated document in an annual report. Most new investors skip straight to earnings - perhaps not knowing how importance the balance sheet is or having an appreciate but not knowing how to read…

ByNick SundichApril 21, 2026

Sick Charts: Why The ASX’s 3 Pathology Stocks Are All Under the Weather

The ASX's 3 pathology stocks: Sonic Healthcare (ASX:SHL), Healius (ASX:HLS) and Australian Clinical Labs (ASX:ACL); have delivered a torrid experience for shareholders over the past two to three years.Sonic, the global heavyweight, has fallen nearly 20% since early 2025 and recently traded at decade lows. Healius, long the sector’s problem child, has lost more than…

ByNick SundichApril 15, 2026

The Iran Ceasefire Rally Is On! But Investors Aren’t Responding In the Right Way

Add a new term to your vocabulary: The Iran Ceasefire Rally. The rally on the ASX yesterday, that saw our bourse rise over 2.5% in its best day in several months, occurred amidst a 2 week suspension of hostilities in Iran. And the ASX was not alone with Asian markets and North American futures rallying,…

ByNick SundichApril 9, 2026

ASX Biotech Investing In 2026: Investors Are More Aware Of The Hard Lessons, But Have Forgotten The Hidden Rewards Of It

ASX Biotech Investing has always been the market’s most difficult arena. Yes tech and resources are risky spaces too, but at least a gold explorer can gain just off the back of gold price momentum or activity from neighbouring peers.With biotech it is all on the success of the individual company. The science is extraordinary…

ByNick SundichApril 7, 2026

The Long Goodbye: Why Australian Active Fund Managers Are Running Out of Road

Australian Active Fund Managers are struggling, make no mistake. Hitting home the point yesterday were reports that Ox Capital Management — a boutique emerging markets specialist led by veteran investor Joseph Lai; had entered formal wind-up proceedings on March 27 2026.This wind up was not the first, and likely won't be the last. So each…

ByNick SundichApril 2, 2026

Here are 5 ASX Stocks That Should Be Merged or Be Acquired, and Why the Logic Is Compelling

Despite the dour state of the markets right now, it could be time for certain ASX stocks that should be merged or be acquired to go ahead. With private equity sitting on nearly USD$440bn in uncommitted capital, a more permissive regulatory environment for smaller deal-making, and a wave of ASX small and mid-caps trading at…

ByNick SundichApril 1, 2026

Here Are 6 Questions Investors Need To Ask About Their Portfolio To Get The Best Possible Returns!

There are hard questions investors need to ask about their portfolio every now and again, because anyone telling you there's such a thing as a 'set and forget' investment is wrong. Markets evolve, company fundamentals shift, and macro conditions change, yet many portfolios are left largely unchecked. The most rational approach is to periodically interrogate…

ByNick SundichMarch 31, 2026

The Impact of The Iran War Extends Beyond Oil, And this ASX Company is the Poster Child for It!

It is easy to think the Impact of The Iran War is simply businesses in the oil space or that use oil in their operations (for instance freight businesses). Or by extension, companies in the 'consumer discretionary' space that find due to higher energy prices (and interest rates), that their goods are more discretionary than…

ByNick SundichMarch 25, 2026

Rhythm Biosciences’ ColoSTAT has been commercialised and the roll out will ramp up fast!

Rhythm Biosciences' colorectal cancer test ColoSTAT is officially on the market and has made its first sale. In our view, this could mark the beginning of a major few years for this company. What are the Best ASX Stocks to invest in right now? Check our buy/sell tips[sg_popup id="23914" event="click"][/sg_popup] ColoSTAT is commercialised, albeit not as investors…

ByNick SundichMarch 18, 2026

the Kick-ass Multipurpose WordPress Theme

Life Sciences

Dimerix And Its DMX-200 (Qytovra) Therapy Approach Their Most Important Catalyst

How To Read a Balance Sheet As An Investor: The 7 Questions Prudent Investors Need to Ask!

Sick Charts: Why The ASX’s 3 Pathology Stocks Are All Under the Weather

The Iran Ceasefire Rally Is On! But Investors Aren’t Responding In the Right Way

ASX Biotech Investing In 2026: Investors Are More Aware Of The Hard Lessons, But Have Forgotten The Hidden Rewards Of It

The Long Goodbye: Why Australian Active Fund Managers Are Running Out of Road

Here are 5 ASX Stocks That Should Be Merged or Be Acquired, and Why the Logic Is Compelling

Here Are 6 Questions Investors Need To Ask About Their Portfolio To Get The Best Possible Returns!

The Impact of The Iran War Extends Beyond Oil, And this ASX Company is the Poster Child for It!

Rhythm Biosciences’ ColoSTAT has been commercialised and the roll out will ramp up fast!

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Life Sciences

Stocks in Spotlight

Add Your Heading Text Here